REGENXBIO/$RGNX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About REGENXBIO
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Ticker
$RGNX
Sector
Primary listing
Employees
353
Headquarters
Website
REGENXBIO Metrics
BasicAdvanced
$465M
-
-$3.43
1.11
-
Price and volume
Market cap
$465M
Beta
1.11
52-week high
$12.56
52-week low
$5.04
Average daily volume
614K
Financial strength
Current ratio
3.127
Quick ratio
2.873
Long term debt to equity
104.521
Total debt to equity
127.149
Interest coverage (TTM)
-5.52%
Profitability
EBITDA (TTM)
-148.753
Gross margin (TTM)
82.44%
Net profit margin (TTM)
-112.70%
Operating margin (TTM)
-105.66%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-17.88%
Return on equity (TTM)
-62.49%
Valuation
Price to revenue (TTM)
3.02
Price to book
2.17
Price to tangible book (TTM)
2.17
Price to free cash flow (TTM)
-5.187
Free cash flow yield (TTM)
-19.28%
Free cash flow per share (TTM)
-1.774
Growth
Revenue change (TTM)
74.95%
Earnings per share change (TTM)
-34.39%
3-year revenue growth (CAGR)
-31.48%
10-year revenue growth (CAGR)
45.59%
3-year earnings per share growth (CAGR)
18.86%
10-year earnings per share growth (CAGR)
-5.31%
What the Analysts think about REGENXBIO
Analyst ratings (Buy, Hold, Sell) for REGENXBIO stock.
Bulls say / Bears say
Closed a non-dilutive royalty bond deal that brings in $150 million upfront and gives the company funding into early 2027, lessening dilution risk and supporting late-stage programs with no new equity (PRNewswire)
FDA accepted the BLA for RGX-121 with Priority Review, setting a PDUFA date of November 9, 2025. This establishes the first-in-class, one-time gene therapy for MPS II as a near-term growth driver (PRNewswire)
Interim data from the Phase I/II AFFINITY DUCHENNE trial show RGX-202 participants surpassing matched natural history controls in key motor functions and no serious adverse events, supporting its strong profile and the move into accelerated pivotal testing (PRNewswire)
Pivotal data for ABBV-RGX-314 in wet AMD—a major partnered program with AbbVie—won’t be available until 2026, pushing back hopes for royalties or commercial returns to the medium term (PRNewswire)
The pivotal AFFINITY DUCHENNE trial for RGX-202 is only about halfway enrolled as of Q1 2025. The company doesn’t expect to file its BLA until mid-2026, so any revenue from Duchenne gene therapy likely won’t come until late 2026 or later (PRNewswire)
REGENXBIO is dependent on its partner Nippon Shinyaku to bring RGX-121 to market in key areas, which could narrow margins and adds the risk of execution or royalty shortfalls when approved (PRNewswire)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.
REGENXBIO Financial Performance
Revenues and expenses
REGENXBIO Earnings Performance
Company profitability
REGENXBIO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for REGENXBIO stock?
REGENXBIO (RGNX) has a market cap of $465M as of September 17, 2025.
What is the P/E ratio for REGENXBIO stock?
The price to earnings (P/E) ratio for REGENXBIO (RGNX) stock is 0 as of September 17, 2025.
Does REGENXBIO stock pay dividends?
No, REGENXBIO (RGNX) stock does not pay dividends to its shareholders as of September 17, 2025.
When is the next REGENXBIO dividend payment date?
REGENXBIO (RGNX) stock does not pay dividends to its shareholders.
What is the beta indicator for REGENXBIO?
REGENXBIO (RGNX) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.